IRLAB A
14.35
SEK
TODAY
-0.69 %
TODAY SEK
-0.10 SEK
17:00:00
2024-02-23
YEAR LOW
7.6 SEK
YEAR HIGH
18 SEK
ATH:
108.09 SEK
MCAP:
744 MSEK

CEO COMMENTS

Gunnar Olsson comments Q4 report 2023

“We have recently completed the compilation of a Briefing Package on mesdopetam as part of the preparations for the upcoming end-of-Phase 2 meeting with the FDA. The agency has confirmed a meeting with us scheduled for February 20. This is an important milestone towards finalizing the planning of Phase III for mesdopetam. In December, the highly respected The Michael J. Fox Foundation announced that it had decided to finance IRLAB and the company’s work with the substance IRL757 for the treatment of apathy with just over 2 million USD to conduct a clinical Phase I study. Both of these events are remarkable as they both constitute external validation and reinforce the quality of the research and development work that IRLAB conducts. I would also like to take this opportunity to give praise to all employees who have contributed to these acknowledgments from world-leading evaluators of pharmaceutical projects.”

LATEST REPORTS

LATEST PRESS RELEASE
FEBRUARY 22, 2024 / REGULATORY

IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam

Gothenburg, Sweden, 22 February 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s recent End-of-Phase 2 meeting with the US Food and Drug administration, FDA, was held in a constructive and engaging spirit. The discussions during the meeting indicate alignment between the FDA and IRLAB on the design of the Phase III program.

Read More >
LATEST PRESENTATION
NOVEMBER 23, 2023

Q&A session on Redeye Life Science Day

Gunnar Olsson, CEO, and Nicholas Waters, EVP and Head of R&D, participated in Redeye Life Science Day on November 23, 2023. Watch the 20-minute Q&A session via link below.

Read More >

FINANCIAL CALENDAR

NEXT

week 18 (April 29-May 3)

Annual report

FOLLOWING

May 8, 2024

Interim report January-March 2024